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countries, increasing to 10% and higher among 
people older than 70 years of age.2 Moreover, 
HF has become the main cause of hospitaliza‑
tion in patients older than 65 years.2,3 It is sug‑
gested that the rising prevalence of HF results 
from population aging and improved treatment 
IntroductIon Despite significant progress in 
the diagnosis and treatment of cardiovascular 
disease (CVD) in recent decades, the incidence 
and prevalence of heart failure (HF) continues 
to rise.1 The prevalence of HF is approximately 
1% to 2% of the adult population in developed 
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AbstrAct
IntroductIon The management of heart failure (HF) has changed significantly in recent decades.
objEctIvEs We analyzed the clinical profile, 1 ‑year outcomes, predictors of mortality, and hospital 
readmissions in hospitalized patients enrolled in the European Society of Cardiology Heart Failure Pilot 
Survey (ESC ‑HF Pilot) and Heart Failure Long ‑Term Registry (ESC ‑HF ‑LT).
PAtIEnts And mEthods The analysis included hospitalized Polish patients from both registries. The primary 
endpoint was all ‑cause death at 1 year, while the secondary endpoint was all ‑cause death or hospitaliza‑
tion for worsening HF at 1 year.
rEsuLts The study included a total of 1415 hospitalized patients (650 from ESC ‑HF Pilot; 765 from ESC‑
‑HF ‑LT). The primary endpoint occurred in 89 of the 650 patients (13.7%) and in 120 of the 711 patients 
(16.9%) from ESC ‑HF Pilot and ESC ‑HF ‑LT, respectively (P = 0.11). The secondary endpoint was more 
frequent in ESC ‑HF Pilot than in ESC ‑HF ‑LT (201 of 509 [39.5%] vs 222 of 663 [33.5%]; P = 0.04). Com‑
pared with ESC ‑HF Pilot, patients from the ESC ‑HF ‑LT registry were older and more often had hypertension, 
atrial fibrillation, peripheral artery disease, and chronic kidney disease, while the incidence of chronic 
obstructive pulmonary disease was lower. The percentage of patients receiving drugs for HF (diuretics, 
angiotensin ‑converting enzyme inhibitors, angiotensin receptor blockers, β ‑blockers, mineralocorticoid 
receptor antagonists), anticoagulants, cardiac resynchronization therapy, and implantable cardioverter‑
‑defibrillator were higher in the ESC ‑HF ‑LT group in comparison with the ESC ‑HF Pilot group.
concLusIons Patients from the ESC ‑HF ‑LT registry had a lower risk of death or hospitalization for worsening 
HF despite the fact that they were older and had more comorbidities. The results might suggest an im‑
provement in physicians’ adherence to the guidelines on the management of HF in the ESC ‑HF ‑LT registry.
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echocardiographic features of left ventricular dys‑
function. There were no specific exclusion crite‑
ria. All patients provided written informed con‑
sent. The surveys were approved by a local eth‑
ical review board.
The ESC ‑HF Pilot registry enrolled patients 
on a single day of the week (chosen by the par‑
ticipating center) from October 2009 to May 
2010 in 136 European cardiology centers, includ‑
ing 29 centers from Poland. Patients recruited in 
ESC ‑HF Pilot were not subsequently included in 
the ESC ‑HF ‑LT registry. ESC ‑HF ‑LT is a 3 ‑phase 
registry conducted in 211 centers from 21 Eu‑
ropean countries. During phase I of the regis‑
try, covering the period from May 2011 to April 
2013, patients were enrolled on the first day of 
the week for 12 consecutive months. In phases 
II and III of the registry, patients were enrolled 
during 5 consecutive days every quarter. Phase 
III is currently ongoing.4
The current analysis included hospitalized Pol‑
ish patients enrolled in ESC ‑HF Pilot and in phase 
I of ESC ‑HF ‑LT (FIGurE 1). Ambulatory patients 
were excluded. In both registries, the primary 
endpoint was all ‑cause death at 1 year, where‑
as the secondary endpoint was all ‑cause death 
or hospitalization for worsening HF at 1 year. 
We compared the characteristics and 1 ‑year out‑
comes between patients enrolled in both regis‑
tries and determined the predictors of the pri‑
mary and secondary endpoints in these popula‑
tions. Data gathered in both registries included 
demographic characteristics, diagnostic test re‑
sults, medical history, clinical presentation at ad‑
mission and at discharge, management during in‑
dex hospitalization, previous and current treat‑
ment, and 1 ‑year follow ‑up. Case report forms 
enabled investigators to choose between “nev‑
er,” “former,” “sometimes,” or “daily” for alco‑
hol consumption.
of CVD. Moreover, there has been an increase 
in the number of patients with left ventricular 
dysfunction, which is a consequence of success‑
fully treated acute coronary syndromes.1,3 HF 
still has a poor prognosis associated with high 
rates of hospital readmissions and increasing 
treatment costs.1,3
It has been suggested that the care of HF 
patients may be improved by participation in 
registries and clinical trials.4 The Heart Failure 
Association of the European Society of Cardi‑
ology (ESC)5 has initiated the Heart Failure Pi‑
lot Survey (ESC ‑HF Pilot) and subsequently 
the Heart Failure Long ‑Term Registry (ESC ‑HF‑
‑LT). These are prospective multicenter observa‑
tional registries aiming to evaluate the clinical 
profile, pharmacotherapy, and 1 ‑year outcomes 
of HF patients in European countries.1,3 In re‑
cent years, the management of HF has changed 
markedly. Therefore, the current study aimed 
to analyze and compare the characteristics and 
1 ‑year outcomes as well as predictors of mor‑
tality and hospital readmissions in hospitalized 
patients enrolled in the ESC ‑HF Pilot and ESC‑
‑HF ‑LT registries.
PAtIEnts And mEthods The ESC ‑HF Pilot 
and ESC ‑HF ‑LT registries were multicenter pro‑
spective observational surveys of HF patients. 
The registries included outpatients and inpa‑
tients with chronic, worsening, or new ‑onset HF. 
Patients who were over 18 years of age and met 
the diagnostic criteria for HF (both outpatients 
and patients hospitalized for acute or chron‑
ic HF) were enrolled. HF was diagnosed accord‑
ing to the typical clinical signs and symptoms 
as well as biochemical findings (increased lev‑
els of N ‑terminal fragment of the prohormone 
brain natriuretic peptide ≥125 pg/ml or brain 
natriuretic peptide ≥35 pg/ml) and, optionally, 
FIGurE 1 Flow chart 
of patient enrollment in 
the study 
Abbreviations: HF, heart 
failure
12 440 patients in the ESC‑HF‑LT registry (Phase I) 
5118 patients in the ESC‑HF Pilot registry
1415 patients hospitalized for HF
604 outpatients
2019 patients enrolled in Polish 
centers
1361 patients for the primary 
endpoint analysis
1172 patients for the secondary 
endpoint analysis
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recommended HF drugs at admission and at dis‑
charge are presented in tAbLE 4.
Patients from the ESC ‑HF ‑LT registry were 
admitted with a significantly higher New York 
Heart Association (NYHA) class than those from 
ESC ‑HF Pilot (median [IQR], 3 [3–4] and 3 [2–4], 
respectively; P = 0.01). During index hospital‑
ization, death occurred in 42 of the 1415 pa‑
tients (2.97%), including 20 of the 650 patients 
from the ESC ‑HF Pilot registry (3.1%) and 22 of 
the 765 patients from the ESC ‑HF ‑LT registry 
(2.9%; P = 0.88). The primary endpoint was 
reached by 209 of the 1361 patients (15.4%). 
In the ESC ‑HF Pilot registry, the primary end‑
point occurred in 89 of the 650 patients (13.7%), 
whereas in the ESC ‑HF ‑LT registry the all ‑cause 
death at 1 year was observed in 120 of the 711 pa‑
tients (16.9%; P = 0.11). The secondary endpoint 
occurred in 423 of the 1172 patients (36.1%), in‑
cluding 201 of the 509 patients from ESC ‑HF 
Pilot (39.5%) and 222 of the 663 patients from 
ESC ‑HF ‑LT (33.5%; P = 0.04) (tAbLE 3). The Ka‑
plan–Meier curves for the primary and second‑
ary endpoints in the ESC ‑HF Pilot and ESC ‑HF‑
‑LT registries are presented in FIGurEs 2 and 3.
The univariate analyses of predictors of the pri‑
mary and secondary endpoints for both registries 
were performed. Variables that were predictive of 
the endpoint (and maintained an adequate EPV 
value) were consequently included in the mul‑
tivariate Cox proportional hazards regression 
models (tAbLE 5).
dIscussIon This observational study revealed 
less frequent readmission rates during follow‑
‑up in patients enrolled in the ESC ‑HF ‑LT than 
statistical analysis For the  comparison of 
group characteristics, the Fisher exact test and 
the Mann–Whitney test were used for categor‑
ical and continuous variables, respectively. To 
identify predictors of the primary and second‑
ary endpoints, the Cox proportional hazards re‑
gression model was used. Variables found to be 
significant in univariate analyses were includ‑
ed in multivariate analyses. To maintain an ad‑
equate value of the events per predictor variable 
(EPV), variables with an incompleteness of data 
greater than 5% were not included in the Cox 
model due to the relatively small size of the an‑
alyzed groups. A P value of less than 0.05 was 
considered significant for all tests. The tests were 
2 ‑tailed. The Kaplan–Meier curves were devel‑
oped for the primary and secondary endpoints of 
the ESC ‑HF Pilot and ESC ‑HF ‑LT registries sep‑
arately (FIGurEs 2 and 3). Statistical analyses were 
performed using the SPSS software (IBM SPSS 
Statistics 22, Armonk, New York, United States).
rEsuLts The ESC ‑HF Pilot and ESC ‑HF ‑LT 
(phase I) registries enrolled 5118 and 12 440 pa‑
tients across Europe, respectively. The total Pol‑
ish cohort was 2019 patients. The final analysis 
included 1415 inpatients: 650 from ESC ‑HF Pi‑
lot and 765 from ESC ‑HF ‑LT. Data on 1 ‑year sur‑
vival were available for 1361 of the 1415 patients 
(96.2%). Data on 1 ‑year survival or readmission 
for decompensated HF were available for 1172 of 
the 1415 patients (82.8%).
The baseline characteristics, clinical course, 
pharmacotherapy, in ‑hospital management, and 
long ‑term outcomes of the total population are 
presented in tAbLEs 1, 2, and 3. The mean doses of 
FIGurE 2 Kaplan–
Meier curves for all‑
‑cause 1 ‑year mortality 
in Polish patients 
enrolled in the ESC ‑HF 
Pilot and ESC ‑HF ‑LT 
registries
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due to the aging of the general population. The re‑
sults of both registries confirm that the ischemic 
etiology is the most frequent primary cause of HF 
in the Polish population, which is consistent with 
previous observations.3 In both registries, the isch‑
emic etiology of HF was recorded in 57.7% of pa‑
tients. There was a slight decrease in the percent‑
age of ischemic ‑related HF observed for the Pol‑
ish cohort of ESC ‑HF ‑LT compared with ESC ‑HF 
in the ESC ‑HF Pilot registry, which might sug‑
gest an improvement in symptomatic treatment 
of HF in recent years. Although patients includ‑
ed in ESC ‑HF ‑LT were older and had more comor‑
bidities, there were no significant differences in 
1 ‑year mortality between the registries.
Interestingly, the population of patients enrolled 
in ESC ‑HF ‑LT was significantly older compared 
with the population in ESC ‑HF Pilot, which is likely 
tAbLE 1 Baseline characteristics of patients with heart failure included in the ESC‑HF Pilot and ESC‑HF‑LT registries
Characteristics Total (n = 1415) ESC ‑HF Pilot (n = 650) ESC ‑HF ‑LT (n = 765) P value
Demographic data
Male sex 66.0%; 934/1415 64.3%; 418/650 67.5%; 516/765 0.22
BMI, kg/m2 28 (25–31); n = 1335 28 (25–31); n = 573 28 (25–31); n = 762 0.66
Age, y 69 (59–78); n = 1415 69 (58–78); n = 650 70 (61–78); n = 765 0.03
Heart failure
LVEF, % 36 (25–50); n = 1229 37 (26–50); n = 568 35 (25–50); n = 738 0.20
HFpEF 26%; 340/1306 25.0%; 142/568 26.8%; 198/738 0.48
HFrEF 56.4%; 736/1306 55.6%; 316/568 56.9%; 420/738 0.65
HFmrEF 17.6%; 230/1306 19.4%; 110/568 16.3%; 120/738 0.16
Previous HF hospitalization 54.6%; 771/1412 57.6%; 374/649 52.0%; 397/763 0.04
Ischemic etiology 57.7%; 816/1414 60.6%; 393/649 55.3%; 423/765 0.05
Dilated cardiomyopathy 12.7%; 179/1415 9.7%; 63/650 15.2%; 116/765 0.002
Medical history
Hypertension 68.9%; 973/1413 66.0%; 429/650 71.3%; 544/763 0.03
AF 43.6%; 616/1412 38.9%; 252/647 47.6%; 364/765 0.001
CAD 56.2%; 795/1414 59.0%; 383/649 53.9%; 412/765 0.05
Prior PCI or CABG 34.0%; 481/1414 32.8%; 213/649 35.0%; 268/765 0.40
PAD 12.7%; 180/1413 8.9%; 58/650 16.0%; 122/763 <0.001
Diabetes 35.1%; 497/1415 35.1%; 228/650 35.2%; 269/765 1.00
CKD 20.9%; 296/1413 12.3%; 80/648 28.2%; 216/765 <0.001
COPD 18.8%; 265/1413 23.3%; 151/649 14.9%; 114/764 <0.001
Stroke 10.6%; 150/1413 10.2%; 66/648 11.0%; 84/765 0.67
Current smoking 56.5%; 786/1390 57.1%; 357/625 56.1%; 429/765 0.70
Alcohol (former or sometimes) 55.8%; 763/1367 48.6%; 301/619 61.8%; 462/748 <0.001
Anemia 32.9%; 466/1415 33.1%; 215/650 32.8%; 251/765 0.96
Previous pharmacotherapy
Diuretics 67.1%; 926/1380 62.3%; 383/615 71.0%; 543/765 0.001
MRA 44.9%; 618/1376 41.7%; 255/611 47.5%; 363/765 0.04
ACEI 62.9%; 865/1376 61.9%; 378/611 63.7%; 487/765 0.50
ARB 8.4%; 116/1373 7.9%; 48/608 8.9%; 68/765 0.56
β ‑Adrenolytic 74.5%; 1025/1376 71.8%; 439/611 76.6%; 586/765 0.047
CCB 13.2%; 181/1375 11.1%; 68/610 14.8%; 113/765 0.05
Statins 54.9%; 756/1376 52.9%; 323/611 56.6%; 433/765 0.17
Anticoagulants 31.35; 431/1377 27.1%; 166/612 34.6%; 265/765 0.003
Antiplatelets 53.6%; 737/1376 53.0%; 324/611 54.0%; 413/765 0.74
Digoxin 18.6%; 255/1372 19.3%; 117/607 18.0%; 138/765 0.58
Categorical variables are presented as number and percentage. Continuous variables are presented as median and interquartile range. 
P values of less than 0.05 are considered significant.
Abbreviations: ACEI, angiotensin ‑converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, 
coronary artery bypass grafting; CAD, coronary artery disease; CCB, calcium channel blocker; CKD, chronic kidney disease; COPD, chronic obstructive 
pulmonary disease; HF, heart failure; HFmrEF, heart failure with mid ‑range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, 
heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; PAD, peripheral artery 
disease; PCI, percutaneous coronary intervention
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angiotensin receptor blockers [ARBs] if ACEI is 
not tolerated or contraindicated) in addition to 
a β ‑blocker are recommended for symptomatic 
patients with HF with reduced ejection fraction 
(HFrEF) to reduce the risk of HF ‑related hospi‑
talization and death.2 The treatment strategy 
for patients with HF with preserved (HFpEF) 
or mid ‑range ejection fraction (HFmrEF) mainly 
depends on coexisting cardiovascular and non‑
cardiovascular comorbidities. However, numer‑
ous clinical trials have shown that only margin‑
ally fewer patients with HFpEF or HFmrEF re‑
ceive β ‑blockers, ACEIs, or ARBs in comparison 
with the HFrEF group.2 In both ESC ‑HF reg‑
istries, the percentages of patients receiving 
ACEIs, ARBs, or β ‑blockers prior to hospitaliza‑
tion were 62.9%, 8.4%, and 74.5%, respective‑
ly. The analysis of the ESC ‑HF ‑LT registry re‑
vealed a slightly higher percentage of patients 
receiving recommended HF drugs in comparison 
with the ESC ‑HF Pilot registry; however, signifi‑
cance was only reached in the case of β ‑blockers 
(ACEIs, 63.7% vs 61.9%, P = 0.50; ARBs, 8.9% vs 
7.9%, P = 0.56; and β ‑blockers, 76.6% vs 71.8%, 
P = 0.047). Interestingly, the recently published 
results for the population of ESC ‑HF ‑LT report‑
ed that 90.0% of outpatients with chronic HF 
Pilot (55.3% vs 60.6%; P = 0.05). This trend is re‑
flected in the results from other registries (AT‑
TEND [Acute Decompensated Heart], 33%; AD‑
HERE [Acute Decompensated Heart Failure Na‑
tional Registry], 57%; EHFS ‑II [EuroHeart Failure 
Survey II], 30%; OPTIMIZE ‑HF [Organized Pro‑
gram to Initiate Lifesaving Treatment in Hospital‑
ized Patients With Heart Failure], 46%).6-9 More‑
over, the results obtained from the pan ‑European 
ESC ‑HF Pilot registry revealed that in the group of 
all outpatients and patients admitted with acute 
HF (AHF), the ischemic etiology was more prev‑
alent in chronic HF than in AHF (84.9% vs 64%). 
The analysis of the ESC ‑HF ‑LT registry suggested 
that the ischemic etiology was more prevalent in 
hospitalized patients with AHF (53.8% vs 43.1% of 
outpatients with chronic HF), especially in the Mid‑
dle East (Israel, 59.1%), followed by northern Eu‑
rope (48%), eastern Europe (47.4%), North Africa 
(44.7%), southern Europe (41.4%), and western Eu‑
rope (32.7%).4,5 The lower percentage of the isch‑
emic etiology of HF in Polish patients from ESC‑
‑HF ‑LT compared with ESC ‑HF Pilot may reflect 
a recent trend in Poland towards more optimal pre‑
vention and treatment of ischemic heart disease.
According to the latest ESC guidelines, angio‑
ten sin ‑converting enzyme inhibitors (ACEIs) (or 
tAbLE 2 Clinical course of index hospitalization of patients with heart failure included in the ESC‑HF Pilot and ESC‑HF‑LT registries
Characteristics Total (n = 1415) ESC ‑HF Pilot (n = 650) ESC ‑HF ‑LT (n = 765) P value
Clinical status at admission
NYHA class 3 (3–4); n = 1408 3 (2–4); n = 646 3 (3–4); n = 762 0.01
SBP, mm Hg 130 (110–145); n = 1412 130 (115–150); n = 647 130 (110–140); n = 765 0.001
DBP, mm Hg 80 (70–90); n = 1411 80 (70–90); n = 647 80 (70–85); n = 764 0.003
Heart rate, bpm 80 (70–100); n = 1412 80 (70–100); n = 647 80 (70–100); n = 765 0.80
AF as a cause of admission 25.2%; 356/1414 17.3%; 112/649 31.9%; 244/765 <0.001
ACS as a cause of admission 19.3%; 273/1412 29.7%; 192/647 10.6%; 81/765 <0.001
Cardiogenic shock 2.5%; 34/1354 2.7%; 16/589 2.4%; 18/765 0.73
Inotropes 12.1%; 170/1410 10.5%; 68/647 13.4%; 102/763 0.10
Diuretics IV 67.4%; 950/1410 78.3%; 508/649 58.1%; 442/761 <0.001
Nitrates IV 13.9%; 196/1409 15.7%; 102/648 12.4%; 94/761 0.08
Clinical signs at admission
Pulmonary rales 58.8%; 832/1415 55%; 357/650 62.1%; 475/765 0.01
Peripheral edema 49.4%; 699/1415 48.2%; 313/650 50.5%; 386/765 0.39
Jugular venous distension (>6 cm) 13.4%; 190/1415 12.5%; 81/650 14.2%; 109/765 0.35
S3 gallop 15.6%; 221/1415 12.6%; 82/650 18.2%; 139/765 0.54
Pleural effusion 14.4%; 204/1415 10%; 65/650 18.2%; 139/765 <0.001
Peripheral hypoperfusion 12.4%; 176/1415 9.8%; 64/650 14.6%; 112/765 0.006
Laboratory findings at admission
Serum sodium, mmol/l 139 (136–141); n = 1401 138 (136–141); n = 642 139 (136–141); n = 759 0.001
Serum potassium, mmol/l 4.4 (4.1–4.8); n = 1401 4.4 (4.0–4.7); n = 641 4.5 (4.1–4.8); n = 760 0.02
Serum creatinine, mg/dl 1.1 (0.9–1.4); n = 1381 1.1 (0.9–1.4); n = 620 1.1 (0.9–1.4); n = 761 0.83
Hemoglobin, g/dl 13.4 (12.0–14.5); n = 1394 13.3 (12.0–14.5); n = 636 13.4 (12.1–14.5); n = 758 0.49
Continuous variables are presented as median and interquartile range. Categorical variables are presented as number and percentage.
P values of less than 0.05 are considered significant.
Abbreviations: ACS, acute coronary syndrome; DBP, diastolic blood pressure; IV, intravenous; NYHA, New York Heart Association; SBP, systolic blood 
pressure; others, see tAbLE 1
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In terms of the differences in pharmacotherapy 
between both registries, a significantly higher per‑
centage of patients received anticoagulant ther‑
apy in ESC ‑HF ‑LT than in ESC ‑HF Pilot, which 
was reported previously.11 This may result from 
the observed trend towards a higher prevalence 
of atrial fibrillation in the ESC ‑HF ‑LT registry as 
well as an improvement in physicians’ adherence 
to the guidelines.
Our analysis revealed that the overall 1 ‑year 
rate of all ‑cause death among hospitalized HF 
patients in Poland was 15.4%, and there was no 
difference between the registries. However, pa‑
tients from the ESC ‑HF ‑LT registry were admit‑
ted with significantly more advanced HF accord‑
ing to the NYHA class. Importantly, there were 
no significant differences in the prescription of 
enrolled from eastern Europe receive an ACEI 
or ARB and 90.8% of them receive a β ‑blocker, 
whereas in the AHF group, the respective per‑
centages are 66.7% and 69.4%.4
Cardiac resynchronization therapy (CRT) and 
implantable cardioverter ‑defibrillator (ICD) im‑
plantation rates were significantly higher in ESC‑
‑HF ‑LT compared with ESC ‑HF Pilot. This indi‑
cates increased accessibility to implantable de‑
vices and improvement in guideline implemen‑
tation in Poland in recent years. These data are 
in line with the recent QUALIFY study by Opols‑
ki et al10 (Quality of Adherence to Guideline Rec‑
ommendations for Life ‑saving in Heart Failure 
Treatment Survey), who revealed that 20.8% and 
7.7% of ambulatory HFrEF patients had implant‑
ed ICD and CRT, respectively.
tAbLE 3 In ‑hospital and long ‑term outcomes of patients with heart failure included in the ESC‑HF Pilot and ESC‑HF‑LT registries
Characteristics Total (n = 1415) ESC ‑HF Pilot (n = 650) ESC ‑HF ‑LT (n = 765) P value
Major management during index hospitalization; clinical status at discharge
NYHA class 2 (2–3); n = 1386 2 (2–3); n = 643 2 (2–3); n = 743 0.02
SBP, mm Hg 120 (110–130); n = 1383 120 (110–130); n = 640 120 (110–130); n = 743 0.28
DBP, mm Hg 70 (65–80); n = 1380 70 (65–80); n = 640 70 (65–80); n = 740 0.16
Heart rate, bpm 70 (65–80); n = 1372 70 (66–80); n = 629 70 (65–80); n = 743 0.50
Hemoglobin, g/dl 13.0 (11.5–14.3); n = 873 13.0 (11.4–14.3); n = 416 13.0 (11.6–14.3); n = 457 0.92
Serum creatinine, mg/dl 1.1 (0.9–1.4); n = 1010 1.1 (0.9–1.4); n = 456 1.1 (0.9–1.4); n = 554 0.96
Serum sodium, mmol/l 139 (136–141); n = 1082 138 (136–141); n = 491 139 (137–142); n = 591 <0.001
Serum potassium, mmol/l 4.4 (4.1–4.7); n = 1088 4.4 (4.1–4.8); n = 491 4.4 (4.1–4.7); n = 597 0.21
PCI or CABG 12.7%; 179/1411 13.4%; 87/650 12.1%; 92/761 0.47
Pharmacotherapy and devices at discharge
Diuretics 83.4%; 1178/1412 81.1%; 525/647 85.4%; 653/765 0.04
MRA 64.7%; 913/1411 62.8%; 406/646 66.3%; 507/765 0.18
ACEI 73.2%; 1034/1413 72.8%; 472/648 73.5%; 562/765 0.81
ARB 9.4%; 132/1410 8.5%; 55/645 10.1%; 77/765 0.36
β ‑Adrenolytic 87.6%; 1238/1413 86.7%; 562/648 88.4%; 676/765 0.37
CCB 15.4%; 217/1413 15.4%; 100/648 15.3%; 117/765 0.94
Statins 67.2%; 950/1413 68.1%; 441/648 66.5%; 509/765 0.57
Anticoagulants 41.9%; 592/1412 37.7%; 244/647 45.5%; 348/765 0.003
Antiplatelets 63.9%; 903/1413 69.1%; 448/648 59.5%; 455/765 <0.001
Digoxin 24.1%; 341/1413 25.8%; 167/648 22.7%; 174/765 0.19
Amiodarone 10.7%; 151/1413 7.6%; 49/648 13.3%; 102/765 <0.001
Antiarrhythmics 7.6%; 107/1413 9.9%; 64/648 5.6%; 43/765 0.003
Pacemaker 7.5%; 106/1415 9.2%; 60/650 6.0%; 46/765 0.03
CRT 4.0%; 57/1415 1.8%; 12/650 5.9%; 45/765 <0.001
ICD 13.3%; 188/1415 5.8%; 38/650 19.6%; 150/765 <0.001
Death during hospitalization, primary and secondary endpoint
Death during hospitalization 3.0%; 42/1415 3.1%; 20/650 2.9%; 22/765 0.88
1 ‑year all ‑cause death 15.4%; 209/1361 13.7%; 89/650 16.9%; 120/711 0.11
1 ‑year all ‑cause death or 
hospitalization for HF 
worsening
36.1%; 423/1172 39.5%; 201/509 33.5%; 222/663 0.04
Continuous variables are presented as median and interquartile range. Categorical variables are presented as number and percentage.
P values of less than 0.05 are considered significant.
Abbreviations: CRT, cardiac resynchronization therapy; ICD, implantable cardioverter ‑defibrillator; others, see tAbLE 1 and 2
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aged 65 years or older, 14.5% of patients aged 
between 65 and 74 years, and 21.6% of patients 
aged 75 years or older.13 Moreover, the analysis 
of this population revealed that death at 1 ‑year 
occurred in 17% of patients with HFpEF and in 
21% of patients with HFrEF.14
In the current analysis, the risk factors asso‑
ciated with 1 ‑year all ‑cause mortality were only 
partly comparable to the several other studies 
conducted in hospitalized HF patients.15-19 In our 
analysis, the independent predictors of 1 ‑year 
all ‑cause mortality in the total population were 
older age, chronic obstructive pulmonary dis‑
ease (COPD), higher NYHA class at admission, 
lower serum sodium at admission, use of inotro‑
pes during index hospitalization, lower systolic 
blood pressure (SBP) at discharge, higher heart 
rate at discharge, and amiodarone at discharge. 
The prescription of β ‑blockers at discharge was 
associated with a significant decrease in mor‑
tality. In hospitalized Polish patients enrolled in 
the ESC ‑HF Pilot registry, the independent pre‑
dictors of all ‑cause mortality during 1 ‑year follow‑
‑up were a higher NYHA class at admission, ino‑
tropic support during hospitalization, and lower 
estimated glomerular filtration rate at discharge.3
In our previous analysis, we assessed the pre‑
dictors of 1 ‑year all ‑cause death in a group of hos‑
pitalized Polish participants of the ESC ‑HF ‑LT 
therapy for HF (ACEIs/ARBs, β ‑blockers, min‑
eralocorticoid receptor antagonists) at hospital 
discharge between both registries. In the gen‑
eral population of ESC ‑HF Pilot, the 1 ‑year all‑
‑cause mortality rates were 17.4% for hospital‑
ized patients (19.3%, 13.0%, 18.4%, and 24.7% 
in northern, eastern, western, and southern Eu‑
rope, respectively) and 7.2% for ambulatory pa‑
tients (9.0%, 5.0%, 6.2%, and 7.4% in northern, 
eastern, western, and southern Europe, respec‑
tively).12 In the ESC ‑HF ‑LT registry, the 1 ‑year 
mortality rates were 26% for hospitalized patients 
with AHF (21.6%, 27.5%, 36.5%, 29.1%, 24.8%, 
and 29.6% in eastern Europe, Middle East, north‑
ern Europe, North Africa, southern Europe, and 
western Europe, respectively) and 8.3% for out‑
patients with chronic HF (7.9%, 14.9%, 11.3%, 
15.6%, 6.9%, and 7.6% in eastern Europe, Mid‑
dle East, northern Europe, North Africa, south‑
ern Europe, and western Europe, respectively).4 
The insufficient number of outpatient HF clinics 
in Poland results in a greater number of hospi‑
talizations of patients with less severe HF, which 
probably explains the lower mortality rate ob‑
served in the Polish population.3 The analysis ac‑
cording to age revealed that in hospitalized Polish 
participants of the ESC ‑HF ‑LT registry, the all‑
‑cause death at 1 ‑year occurred in 9.1% of pa‑
tients younger than 65 years, 18.5% of patients 
tAbLE 4 Doses of the drugs at admission and at discharge in patients with heart failure included in the ESC‑HF Pilot and ESC‑HF‑LT registries
Drug ESC ‑HF Pilot ESC ‑HF ‑LT
Admission Discharge Admission Discharge
ACEI, mg/d Trandolapril 1.1 (0.82) 1.25 (1.06) – –
Ramipril 5.1 (3.05) 5.35 (3.34) 5.07 (2.97) 5.06 (3.02)
Quinapril 16.3 (12.19) 25.4 (12.66) – –
Perindopril 4.89 (2.19) 5.07 (2.51) 4.64 (2.27) 5.62 (2.72)
Lisinopril 10.63 (5.45) 13.6 (6.97) 15.23 (6.93) 14.79 (6.44)
Enalapril 12.63 (7.26) 17.63 (11.47) 13.26 (8.20) 18.25 (11.04)
Cilazapril 1.22 (1.03) 1.08 (1.16) – –
Captopril 26.24 (14.26) 18.5 (0) 19.98 (5.24) 14.57 (3.58)
ARB,  mg/d Valsartan 144 (35.78) 122.66 (41.31) 116.56 (49.68) 124.60 (66.19)
Telmisartan 80 (21.91) 52 (26.83) – –
Losartan 45.58 (20.63) 50.2 (19.39) 44.02 (17.63) 40.63 (17.73)
Candesartan 12.71 (6.6) 9.2 (3.79) 11.0 (7.77) 11.0 (8.87)
β ‑Adrenolytic, mg/d Sotalol 120 (60.47) 116.36 (37.76) – –
Propranolol 60 (52.92) 120 (0) – –
Nebivolol 5 (1.34) 4.66 (0.88) 4.08 (1.77) 4.21 (1.96)
Metoprolol 57.68 (34.33) 37.31 (34.33) 63.32 (39.25) 70.06 (44.46)
Carvedilol 19.09 (14.41) 19.43 (14.32) 19.33 (14.08) 19.14 (13.41)
Bisoprolol 4.87 (2.24) 4.80 (2.30) 4.34 (2.59) 4.61 (2.82)
Betaxolol 16.66 (5.77) 13.33 (5.77) – –
Atenolol 50 (43.3) 100 (0) – –
MRA, mg/d Spironolactone 38.37 (24.29) 37.63 (23.07) 34.42 (22.06) 34.43 (20.75)
Eplerenone 32.91 (12.16) 31.49 (11.01) 30.3 (10.3) 32.53 (11.53)
Data are presented as mean (SD).
Abbreviations: see tAbLE 1
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and age.15 Moreover, a recent study has shown 
that acute kidney injury is significantly associ‑
ated with a higher risk of mortality in hospital‑
ized patients with HFmrEF, as compared with 
the HFrEF group.21
In the combined Polish cohort of both regis‑
tries, the secondary endpoint (death or hospital‑
ization) occurred in 36.1% of patients. A compar‑
ison between ESC ‑HF Pilot and ESC ‑HF ‑LT re‑
vealed a reduced rate of the secondary endpoint in 
the ESC ‑HF ‑LT group (33.5% vs 39.5%, P = 0.04). 
This is an interesting finding, particularly because 
the Polish population in the ESC ‑HF ‑LT registry 
appeared to be significantly older in comparison 
with the ESC ‑HF Pilot group. Moreover, patients 
in ESC ‑HF ‑LT more often had comorbidities, such 
as atrial fibrillation, hypertension, peripheral ar‑
tery disease, chronic kidney disease (CKD), and 
were admitted to the hospital with a significant‑
ly worse clinical status (higher NYHA class, low‑
er blood pressure). Finally, these patients showed 
significantly higher prescription rates of diuret‑
ics at discharge.
In hospitalized Polish participants of the ESC‑
‑HF ‑LT registry, the secondary endpoint (death or 
hospitalization) occurred in 28% of patients aged 
less than 65 years, 36.1% of patients aged 65 years 
or older, 29.2% of patients aged between 65 and 
74 years, and 41.2% of patients aged 75 years or 
older.13 The analysis by ejection fraction revealed 
that the secondary endpoint was reached by 32% 
of patients with HFpEF and 40% of those with 
HFrEF.14 In the ESC ‑HF Pilot registry, the sec‑
ondary endpoint occurred in 35.8% of hospital‑
ized patients with AHF (43.6%, 29.1%, 33.9% and 
registry according to age.13 The independent pre‑
dictors of death in patients aged 65 years or older 
were COPD, SBP, NYHA class, and β ‑blocker use; 
in patients aged between 65 and 74 years, previ‑
ous coronary revascularization, NYHA class, se‑
rum sodium, and creatinine; and in patients aged 
75 years or older, NYHA class and SBP.13 The inde‑
pendent predictors of 1 ‑year mortality in hospi‑
talized Polish patients with HFpEF in this registry 
were age, NYHA class at admission, and moder‑
ate or severe aortic stenosis. In the HFrEF group, 
the predictors included age, NYHA class at admis‑
sion, lower ejection fraction, and lower serum so‑
dium at admission.14
In the OPTIMIZE ‑HF trial, the 60‑ to 90 ‑day 
postdischarge mortality was 8.6% and the rate of 
rehospitalization was 29.6%.16 The factors pre‑
dicting early postdischarge mortality were age, 
serum creatinine, reactive airway disease, liver 
disease, lower SBP, lower serum sodium, lower 
weight at admission, and depression. Prescrip‑
tion of statins and β ‑blockers at discharge was 
associated with significantly lower mortality.19 
In a Korean HF registry of patients hospitalized 
for AHF, the 1 ‑year mortality rate was 15% and 
independent clinical risk factors included age, 
previous history of HF, anemia, hyponatremia, 
high serum levels of N ‑terminal fragment of 
the prohormone brain natriuretic peptide, and 
use of β ‑blockers at discharge.20 In a study con‑
ducted in hospitalized patients with AHF in Swit‑
zerland and Finland, the 1 ‑year mortality rate 
was 29% and its predictors included the presence 
of cardiogenic shock, left ventricular dysfunc‑
tion, renal insufficiency, coronary heart disease, 
FIGurE 3 Kaplan–
Meier curves for all‑
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at admission, lower serum sodium at admission, 
lower serum potassium at admission, use of ino‑
tropes during index hospitalization, intravenous 
use of diuretics during index hospitalization, and 
lower SBP at discharge. Moreover, the predictors 
of the secondary endpoint in the Polish cohort of 
ESC ‑HF Pilot were a history of previous percuta‑
neous coronary intervention or coronary artery 
bypass graft and inotropic support during hos‑
pitalization.3 In the Polish participants of ESC‑
‑HF ‑LT, the independent predictors of all ‑cause 
death or HF ‑related rehospitalization in patients 
46.8% in northern, eastern, western and south‑
ern Europe, respectively) and in 17.6% of ambu‑
latory patients with chronic HF (19.4%, 19.0%, 
21.1% and 16.4% in northern, eastern, western 
and southern Europe, respectively).12 In the ESC‑
‑HF ‑LT registry, the combined endpoint of death 
or HF hospitalization at 1 year was reached by 
36% of patients with AHF and by 14.5% of pa‑
tients with chronic HF.4
In our analysis, the prognostic factors associat‑
ed with the occurrence of the secondary endpoint 
were diabetes, myocardial infarction, NYHA class 
tAbLE 5 Multivariate analyses of predictors of the primary and secondary endpoint in patients with heart failure included in the ESC‑HF Pilot and 
ESC‑HF‑LT registries
Predictor Primary endpoint Secondary endpoint
HR (95% CI) P value HR (95% CI) P value
Age, y 1.03 (1.02–1.05) <0.0001 1.01 (1.00–1.02) 0.24
BMI 0.99 (0.95–1.02) 0.36 – –
CKD 1.16 (0.81–1.68) 0.42 1.09 (0.85–1.40) 0.50
AF 1.07 (0.73–1.58) 0.72 1.07 (0.84–1.35) 0.61
COPD 1.59 (1.11–2.28) 0.01 1.22 (0.95–1.57) 0.13
Anemia 0.94 (0.57–1.56) 0.81 0.91 (0.66–1.28) 0.60
Diabetes – – 1.26 (1.02–1.57) 0.03
Previous HF hospitalization – – 1,23 (0.98–1,54) 0.08
MI – – 1.28 (1.01–1.62) 0.04
PAD 1.29 (0.83–2.01) 0.26 – –
Alcohol (former or sometimes) 0.87 (0.62–1.23) 0.44 0.88 (0.71–1.10) 0.25
NYHA class at admission, per 1 class 1.53 (1.14–2.05) 0.01 1.24 (1.03–1.50) 0.02
NYHA class at discharge, per 1 class 1.19 (0.90–1.57) 0.23 1.19 (0.99–1.44) 0.06
SBP at admission, per 10 mm Hg 1.01 (1.00–1.02) 0.06 1.00 (1.00–1.01) 0.50
SBP at discharge, per 10 mm Hg 0.99 (0.97–1.00) 0.04 0.99 (0.98–1.00) 0.001
DBP at admission, per 10 mm Hg 0.99 (0.98–1.01) 0.50 1.00 (0.99–1.01) 0.40
DBP at discharge, per 10 mm Hg 1.00 (0.98–1.02) 0.91 – –
Heart rate at admission 0.99 (0.99–1.00) 0.08 1.00 (0.99–1.00) 0.64
Heart rate at discharge 1.01 (1.00–1.02) 0.01 1.01 (1.00–1.01) 0.09
Serum sodium at admission, per 1 mmol/l 0.94 (0.91–0.97) <0.0001 0.98 (0.95–1.00) 0.04
Hemoglobin at admission, per 1 g/dl 1.01 (0.89–1.15) 0.91 0.97 (0.89–1.06) 0.52
Creatinine at admission, per 1 mg/dl – – 1.08 (0.93–1.26) 0.31
Potassium at admission, per 1 mmol/l – – 0.78 (0.64–0.94) 0.01
Inotropesa 2.44 (1.61–3.70) <0.0001 1.64 (1.23–2.18) 0.001
Diuretics IVa 1.15 (0.73–1.80) 0.55 1.48 (1.11–1.96) 0.01
ACEI at discharge 0.80 (0.54–1.18) 0.26 0.86 (0.68–1.10) 0.23
β ‑Adrenolytic at discharge 0.58 (0.37–0.91) 0.02 0.78 (0.56–1.08) 0.13
ARB at discharge 0.53 (0.25–1.10) 0.09 – –
Digitalis at discharge 1.34 (0.92–1.95) 0.12 1.21 (0.95–1.54) 0.13
Statin at discharge 1.11 (0.76–1.61 0.60 0.99 (0.77–1.26) 0.92
Antiplatelets at discharge 1.10 (0.75–1.61) 0.63 1.04 (0.81–1.34) 0.74
CCB at discharge 0.77 (0.44–1.34) 0.36 0.92 (0.65–1.30) 0.63
Amiodarone at discharge 1.97 (1.26–3.07) 0.003 – –
P values of less than 0.05 are considered significant.
a During index hospitalization
“–“ means that the variable was not predictive in the univariate analysis.
Abbreviations: CI, confidence interval; HF, heart failure; HR, hazard ratio; MI, myocardial infarction; others, see tAbLEs 1 and 2
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and HF rehospitalization. Recent progress in di‑
agnosis, pharmacotherapy, and interventional 
treatment of HF continuously changes the pa‑
tients’ clinical profile and risk factors for mor‑
tality and HF readmission. It appears that man‑
agement according to the guidelines, as well as 
the ability to assess the individual patient’s risk 
factors, plays an essential role in the successful 
treatment of HF. It is suggested that an assess‑
ment of the epidemiological data of real ‑life pa‑
tients and their risk factors may contribute to 
the adjustment of treatment strategies and re‑
sult in better outcomes.
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